Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
6.5800
0.00 (0.00%)
Recursion Pharmaceuticals Inc is a biotechnology company focused on leveraging advanced computational biology and machine learning techniques to transform drug discovery and development
By utilizing a proprietary platform that integrates high-throughput biology and data science, the company aims to identify new therapeutic targets and accelerate the process of discovering novel medicines for a variety of diseases. Their innovative approach seeks to uncover hidden connections in biological data, enabling them to explore previously uncharted areas in the pharmaceutical landscape and bring forth breakthrough treatments for patients in need.
Previous Close | 6.580 |
---|---|
Open | - |
Bid | 6.700 |
Ask | 6.710 |
Day's Range | N/A - N/A |
52 Week Range | 5.600 - 12.36 |
Volume | 0 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 26,876,608 |
News & Press Releases
Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy.
By Recursion Pharmaceuticals · Via GlobeNewswire · March 18, 2025

Fiserv recently completed its acquisition of Payfare Inc. On "Mad Money Lightning Round," Jim Cramer called it "one of the greatest fintechs."
Via Benzinga · March 10, 2025

Via The Motley Fool · March 8, 2025

Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX.
Via Benzinga · March 8, 2025

Via The Motley Fool · March 7, 2025

The term "game-changing" is overused for too many up-and-coming companies, but in this case, the description fits.
Via The Motley Fool · March 7, 2025

Via The Motley Fool · March 6, 2025

Leerink cited concerns over high cash burn and execution risks in deal-making and clinical development over the next year.
Via Stocktwits · March 2, 2025

Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham.
Via Benzinga · March 3, 2025

Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS.
Via Benzinga · March 1, 2025

SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and fiscal year ended December 31, 2024.
By Recursion Pharmaceuticals · Via GlobeNewswire · February 28, 2025

Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMT
By Recursion Pharmaceuticals · Via GlobeNewswire · February 24, 2025

Nvidia sold their stake in some high-flying stocks recently.
Via The Motley Fool · February 20, 2025

Recursion Pharmaceuticals' stock has soared due to Nvidia's continued investment, positioning the company as a leader in AI-driven drug discovery.
Via MarketBeat · February 21, 2025

The Altitude Lab Fund aims to deliver strong returns to Limited Partners, accelerate the growth of Salt Lake City’s Life Science hub, and enable high potential startups support while federal funding is stalled
By Recursion Pharmaceuticals · Via GlobeNewswire · February 19, 2025

The Japanese conglomerate’s bet comes amid growing AI sector momentum, fueled in part by chipmaking giant Nvidia, which also holds over 7.7 million Recursion shares.
Via Stocktwits · February 18, 2025

Via Benzinga · February 18, 2025

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)
Via Benzinga · February 16, 2025

The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones
By Recursion Pharmaceuticals · Via GlobeNewswire · February 18, 2025

Nvidia's 13F revealed some interesting choices.
Via The Motley Fool · February 14, 2025
Why SoundHound AI and Serve Robotics Stock Crashed on Fridayfool.com
Via The Motley Fool · February 14, 2025